Organon won a label expansion for the steroid-free topical cream it picked up from its October acquisition of Dermavant.

The European Medicines Agency’s human medicines committee (CHMP) handed down 17 recommendations for drug approvals on Friday ...

Boundless Bio is trimming its oncology pipeline in the wake of disappointing cancer data and switching up its leadership just ...

McKinsey fined $650M for helping boost OxyContin sales, misleading FDA about conflicts. Ex-partner Martin Elling charged with ...

The billion-dollar AI-focused startup Xaira Therapeutics deepened its C-suite this week, hiring former Roche executive Paulo ...

Bicycle Therapeutics reports mixed data for zelenectide pevedotin in cancer trials, with 60% response rate in urothelial ...

In an attempt to continue its I&I dominance beyond Humira, Skyrizi and Rinvoq, AbbVie is buying up another small autoimmune ...

Gilead Sciences names Sanofi's Dietmar Berger as new CMO, replacing Merdad Parsey amid challenging year marked by setbacks ...

Repare Therapeutics announced that a combination of two targeted drugs resulted in confirmed responses of 19% and 17% in ...

BeiGene acquires MTAP deletion drug SYH2039 from CSPC for $150M, plans combo with BGB-58067, competing with Ideaya's IDE397 ...

Teos Therapeutics halts inupadenant development after poor Phase 2 NSCLC data, and shifts focus to TIGIT program, a combo of ...

Eisai licenses Newron's evenamide for Asia; Novavax gets $50M from Sanofi; Candel & Inovio price offerings; RemeGen's disitamab vedotin shows success in breast cancer trial ...